Auszug
Ziel jeglicher Diagnostik muss sein, Tumoren im Unterbauch zu identifizieren, sie den verschiedenen möglichen Ursprungsorganen zuzuordnen und zwischen benigne und maligne zu differenzieren. Ausgangspunkt jeder Untersuchung ist eine sorgfältige klinische Anamnese, die Beachtung auch unspezifischer Symptome und eine ausführliche klinische Untersuchung auf der Basis der bimanuellen Tastuntersuchung des kleinen Beckens. Diese klinische Untersuchung wird ergänzt durch die bildgebenden Verfahren, insbesondere den transvaginalen und den transabdominalen Ultraschall sowie die radiologische Diagnostik mittels Computertomogramm und MRT. Wichtig zu wissen ist, dass eine endgültige Dignitätsbeurteilung bisher mit keinem der bildgebenden Verfahren möglich ist.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
DiSaia PJ, Creasman WT; Clinical gynecologic oncology, 7th ed., Mosby & Co., St. Louis, MO, 2007
Hugh R.K. Barber, Edward A. Graber, Tae hae Kwon, Ovarian Cancer, CA Cancer J Clin 1974; 24:340
Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren. Koordination: Prof. Dr. Barbara Schmalfeldt, München, Prof. Dr. Jacobus Pfisterer, Kiel. Zuckschwerdt, München 2007
Manual Maligne Ovarialtumoren; Tumorzentrum München, Zuckschwerdt, München 2007
Literatur
Alcazar JL, Jurado M (1999) Prospective evaluation of logistic model based on sonographic morphologic and color Doppler findings developed to predict adnexal malignancy. J Ultrasound Med 18: 837–842
Alcazar JL, Erasti T, Laparte c, Jurato M, Lopez-Garcia G (2001) Assessment of a new logistic model in the preoperativ evaluation of adnexal masses J Ultrasound Med 20:842–848
Bailey CL, Ueland FR, Land GL et al. (1998) The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol Oncol 69: 3–7
Bundesgeschäftsstelle Qualitätssicherung (2003, 2004, 2005) BQS-Qualitätsreport: Indikation bei Ovarialeingriffen. Verfügbar unter www.bqs-qualitaetsreport.de [5.9.2008]
D’Arcy TJ, Jayaram V, Lynch M, Soutter WP, Cosgrove DO, Harvey GL (2004) Ovarian cancer detected non-invasively by contrast-enhanced Doppler ultrasound. Br J Obstet Gynecol 111: 619–622
DePriest PD, Shenson D, Fried A et al. (1993) A morphology indexed based on sonographic findings in ovarian cancer. Gynecol Oncol 51: 7–11
DGGG, DKG, AGO (2004) Leitlinien, Empfehlungen, Stellungnahmen. 2.2.7 Maligne Ovarialtumoren. AWMF 032/042. Aktualisiert bestätigt März 2004
Ekerhovd E, Wienerroith H, Staudach A, Granberg S (2001) Preoperative assessment of unilocular adrenal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. Am J Obstet Gynecol 184: 48–54
Emoto M, Fujimitsu R, Iwasaki H, Kawarabayashi T (2003) Case 3. Normal-sized ovarian cancer detected by color Doppler ultrasound using a microbubble contrast agent. J Clinical Oncology 19: 3703–3705
Gohagan JK, Prorock PC, Hayes RB, Kramer BS for the PLCO Project Team (2000) The prostate, lung, coloreectal and ovarian (PLCO) cancer screening trial of the National Cancer Institute: History, organization, and status. Controlled Clinical Trials 21: 273S–309S
Guerriero S, Alcazar JL, Coccia ME et al. (2002) Complex pelvic mass as a target for evaluation of vessel distribution by color Doppler sonography for the diagnosis of adnexal malignancies J Ultrasound Medicine 21: 1105–1111
Jacobs IJ, Skates SJ, MacDonald N et al. (1999) Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 354 9160) 1207–210
Kindermann G, Maassen V, Kuhn W (1996) Laparoscopic management of ovarian tumors subsequently diagnosed as malignant. J of Pelvic Surgery 2: 245–251
Kupesic S, Kurjak A (2000) Contrast-enhanced, three dimensional power Doppler Sonography. Obstet Gynecol 96: 452–458
Kurjak SA, Kupesic S, Sparac V, Prka M, Bekavac I (2003) The detection of stage I ovarian cancer by three-dimensional sonography and power Doppler. Gynecol Oncol 90: 258–264
Marret H, Ecohard R, Giraudeau B, Golfier F, Raudrant D, Lansac J (2002) Color Doppler energy prediction of malignancy in adnexal masses using logistic regression models., Ultrasound Obstet Gynecol 20: 597–604
Merz E, Weber G, Bahlmann F, Kießlich R (1998) A new sonomorphologic scoring system (Mainz Score) the assessment of ovarian tumors using transvaginal ultrasonography. Part I Premenopause. Ultraschall Med 19: 99–107
Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio RJ, Nagell JR van (2003) Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 102: 594–599
Nagell JR van, De Priest PD, Reedy MB et al. (2000) The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 77: 350–356
Orden MR, Jurvelin JS, Kirkinen PP (2002) Kinetics of a US contrast agent in benign and malignant adnexal tumors. Radiology 226: 405–410
Osmers R, Osmers M, Maydell B von, Wagner B, Kuhn W (1996) Preoperativ evaluation of ovarian tumors in premenopause by transvaginalsonography. Am J Obstet Gynecol 175: 428–434
Osmers R, Osmers M, Maydell B von, Wagner B, Kuhn W (1998) Evaluation of ovarian tumors in postmenopausal women by transvaginal sonography. Eur J Obstet Gynecol Reprod Biol 77: 81–8
Pfleiderer A (2002) Gutartige Ovarialtumoren und Borderline-Tumoren. Gynäkologe 35: 689–704
Prömpeler HJ, Madjar H, Sauerbrei W, Lattermann U, Pfleiderer A (1994) Quantitative flow measurements for dassification of ovarian tumors by transvaginal color Doppler sonography in postmenopausal patients. Ultrasound Obstet Gynecol 4: 406–413
Prömpeler HJ, Madjar H, Sauerbrei W, Lattermann U, Pfleiderer A (1996) Kombinierte Beurteilung von Ovarialtumoren mit transvaginaler B-Bild-und Farbdoppler-Sonographie. Geburtsh Frauenheilkd 56: 345–350
Prömpeler HJ, Karck U, Madjar H, Lattermann U, Breckwoldt M (1997a) Sonograhische Diagnostik von Dermoidzysten (Sonomorphologie und Vaskularisation). Geburtsh Frauenheilkd 57: 463–467
Prömpeler HJ, Madjar H, Sauerbrei W, Lattermann U, Pfleiderer A (1997b) Diagnostic formula for the differentiation of adnexal tumors by transvaginal sonography. Obstet Gynecol 89: 428–433
Prömpeler HJ, Randelzhofer B, Sauerbrei W, Madjar H (2000) Überprüfung der Diagnose-Formel für Ovarialtumoren. Ultraschall in der Medizin 21: 563
Prömpeler HJ, Watermann D, Emmerich D, Denschlag D, Pauer U, Sauerbrei W (2002) Vaskularisation von Ovarialtumoren. Eine multivariate Analyse. Ultraschall Med 24: 2
Sassone M, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB (1991) Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 78: 70–76
Schelling M, Braun M, Kuhn W et al. (2000) Combined transvaginal D-mode and color Doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis. Gynecol Oncol 77: 78–86
Tekay A, Jouppila P (1996) Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Acta Obstet Gynecol Scand 75: 316–29
Timmermann D (2004) The use of mathematical models to evaluate pelvic masses; can thea beat an expert operator? Best Practice & Research Clinical Obstetrics and Gynecology 18: 91–104
Timmermann D, Verrelst H, Bourne TH, DeMoor B, Collins WP, Vergote I, Vandewalle J (1999) Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses. Ultrasound Obstet Gynecol 13: 17–25
Timmermann D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I (2000) Terms, definition and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol 16: 500–5
Timmermann D, Testa AC, Bourne T et al. (2005) Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the IOTA Group. JCO 23: 8794–8801
Ueland FR, DePriest PD, Pavlik EJ, Kryscio RJ, Nagell JR van (2003) Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol 91: 46–50
Valentin L (1999a) High-quality gynecological ultrasound can be highly beneficial, but poor-quality gynecological ultrasound can do harm Ultrasound Obstet Gynecol 13: 1–7
Valentin L (1999b) Pattern Recognition of pelcic masses by grea-scale ultrasound imaging: the contribution of Doppler ultrasound. Obstet Gynecol 14: 338–347
Valentin L (2000) Comparison of Lerner score, Doppler ultrasound examination, and their combination for discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol 15: 143–147
Valentin L, Sladkevicius P, Marsal K (1994) Limited contribution of Doppler velocimetry to the differential diagnosis of extrauterine pelvic tumors. Obstet Gynecol 83: 425–433
Valentin L, Hagen B, Tingulstad S, Eik-Nes S (2001) Comparison of »pattern recognition« and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation. Ultrasound Obstet Gynecol 18: 357–365
Valentin L, Ameye L, Jurkovic D, Metzger U, Lecuru F, Van Huffel S, Timmerman D (2006) Which extrauterine pelvic masses are difficult to correctly classify as benign or malignant on the basis of ultrasound findings and is there a way of making a correct diagnosis? Ultrasound Obstet Gynecol 27: 438
Weber G, Merz E, Bahlmann F, Leber AM (1999) A new sonomorphologic scoring system (Mainz Score) the assessment of ovarian tumors using transvaginal ultrasonography. Part II Postmenopause. Ultraschall Med 20: 2–8
Literatur
American Cancer Society (1998) Cancer facts and figures: 1998, American Cancer Society, p 13. Verfügbar unter www.cancer.org [29.08.2008]
Imaoka I, Wada A, Kaji Y et al. (2006) Developing an MR imaging strategy fpr diagnosis of ovarian masses. Radiographics 26(5): 1431–1448
Hricak H, Chen M, Coakley FV et al. (2000) Complex adnexal masses: detection and characterization with MR imaging—multivariate analysis. Radiology 214: 39–46
Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST (2002) CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics 22: 1305–1325
Kim SH, Kim WH, Park KJ, Lee JK, Kim SJ (1996) CT and MR findings of Krukenberg tumors: comparison with primary ovarian tumors. J Comput Assist Tomogr 20: 393–398
Kinkel K, Ariche M, Tardivon AA et al. (1997) Differentiation between recurrent tumor and benign-conditions after treatment of gynecolic pelvic carcinoma: value of dynamic contrast-subtraction MR imaging. Radiology 204: 55–63
Kurtz AB, Tsimikas JV, Tempany CM et al. (1999) Diagnosis and staging of ovarian cancer: comparative values of Dopler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis—report of the Radiology Diagnostic Oncology Group. Radiology 212: 19–27
Low RN, Saleh F, Song SY et al. (1999) Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination-a longitudinal study. Radiology 211: 519–528
Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC (1995) Ovarian carcinoma: value of CT in predicting success of debulking surgery. Am J Roentgenol 165: 875–878
Nitzsche EU, Hoh CK, Dalbohm M, Glaspy A, Phelps ME, Moser EA (1993) Ganzkörper-Positronen-Emissions-Tomographie beim Mammakarzinom. Fortschr Röntgenstr 158: 293–298
Outwater EK, Huang AB, Dunton CJ, Talerman A, Capuzzi DM (1997) Papillary projection in ovarian neoplasms: appearance in MRI. J Magn Reson Imaging 7: 689–695
Outwater EK, Siegelman ES, Kim B, Chiowanich P, Blasbalg R, Kilger A (1998) Ovarian Brenner tumors: MR imaging characteristics. Magn Reson Imaging 16: 1147–1153
Rieber A, Nüssle K, Stöhr I et al. (2001) Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. Am J Roentgenol 177: 123–129
Risum S, Hogdall C, Loft A et al. (2007) The diagnostic value of PET/CT for primary cancer—A prospective study. Gynecol Oncol 105: 145–149
Scully RE, Young RH, Clement PB (1996) Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology, Armed Forces Institute of Pathology, Washington.
Tanaka YO, Kurosaki Y, Nishida M et al. (1994) Ovarian dysgerminoma: MR and CT appearance. J Comput Assist Tomogr 18: 443–448
Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ (2000) Staging of advanced ovarian cancer: comparison of imaging modalities—report of the Radiology Diagnostic Oncology Group. Radiology 215: 761–767
Thrall MM, Deloia JA, Gallion H, Avril N (2007) Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 105: 17–22
Togashi K, Nishimura K, Itoh K et al. (1987) Ovarian cystic teratomas: MR imaging. Radiology 162: 669–673
Togashi K (2003) Ovarian cancer: the clinical role of US, CT, and MRI. Eur Radiology 13: L87–L104
Troiano RN, Lazzarini KM, Scout LM, Lange RC, Flynn SD, Mc Carthy S (1997) Fibroma and fibrothecoma of the ovary: MR imaging findings. Radiology 204: 795–798
Young RH, Scully RE (1994) Metastatic tumors of the ovary. In: Kurman RJ (ed) Blaustein’s pathology of the female genital tract. Springer, Berlin Heidelberg New York, pp 939–974
Literatur
An H. J., Kim D. S., Park Y. K. et al., Comparative proteomics of ovarian epithelial tumors, J Proteome Res 5 (2006) 1082–1090 [www. cancer.gov/cancertopics/pdq/screening/overview]
Baekelandt M., Khouja H., Kristensen G. B., Nesland J., Holm R., The potential prognostic and predicitive significance of cell cycle-related proteins Ki-67, p16, p14 and p57 in advanced ovarian cancer. J Clin Oncol 22 (2004), ASCO Annual Meeting Proceedings 2004, Abstract 5042
Barnholtz-Sloan J. S., Tainsky M. A., Abrams J. et al., Ethnic differences in survival among women with ovarian carcinoma. Cancer 94 (2002) 1886–1893
Brockbank E. C., Ind T. E., Barton D. P. et al., Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer, Int J Gynecol Cancer 14 (2004) 42–50
Brose M. S., Rebbeck T. R., Calzone K. A. et al., Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94 (2002) 1365–1372
Brun J. L., Feyler A., Chene G., Saurel J., Brun G., Hocke C., Long-term results and prognostic factors in patients with epithelial ovarian cancer, Gynecol Oncol 78 (2000) 21–27
Brustmann H., Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomer ase II alpha and prognosis, Gynecol Oncol 95 (2004) 16–22
Check E., News feature: Running before we can walk?, Nature 429 (2004) 496–497
Chi D. S., Venkatraman E. S., Masson V., Hoskins W. J., The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma, Gynecol Oncol 77 (2000) 227–231
Codegoni A. M., Broggini M., Pitelli M. R. et al., Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 65 (1997) 130–137
Coleman R., Herzog T., Hosford S. et al., An ex vivo chemoresponse assay predicts carboplatin-induced progression-free interval in ovarian cancer. J Clin Oncol 22, ASCO Annual Meeting Proceedings, (2004), Abstract 5134
Colitti C. V., Rodabaugh K. J., Welch W. R., Berkowitz R. S., Mok S. C., A novel 4 cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas, Oncogene 16 (1998) 555–559
Conrads T. P., Veenstra T. D., The utility of proteomic patterns for the diagnosis of cancer, Curr Drug Targets Immune Endocr Metabol Disord 4 (2004) 41–50
Conrads T. P., Zhou M., Petricoin E. F. 3rd, Liotta L., Veenstra T. D., Cancer diagnosis using proteomic patterns, Expert Rev Mol Diagn 3 (2003) 411–420
Conrads T. P., Fusaro V. A., Ross S. et al., High-resolution serum proteomic features for ovarian cancer detection, Endocr Relat Cancer 11 (2004a) 163–178
Conrads T. P., Hood B. L., Issaq H. J., Veenstra T. D., Proteomic patterns as a diagnostic tool for early-stage cancer: a review of its progress to a clinically relevant tool, Mol Diagn 8 (2004b) 77–85
Daly M. B., R. F. Ozols, The search for predictive patterns in ovarian cancer: proteomics meets bioinformatics, Cancer Cell 1 (2002) 111–112
Diamandis E. P., Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations, Mol Cell Proteomics 3 (2004a) 367–378
Diamandis E. P., OvaCheck: doubts voiced soon after publication, Nature 430 (2004b) 611
Dressman H. K., Berchuck A., Chan G. et al., An integrated genommic based approach to individualized treatment of patients with advanced-stage ovarian cancer, J Clin Oncol 25 (2007) 517–525
Foti E., Ferrandina G., Martucci R. et al., IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels, Oncology 57 (1999) 211–215
Gallion H., Christopherson W., Coleman R. T. et al., Ex vivo chemoresponse assay of ovarian cancers predicts clinical outcome, J Clin Oncol 22, ASCO Annual Meeting Proceedings (2004) Abstract 5074
Gifford G., Paul J., Vasey P. A. et al., The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients, Clin Cancer Res 10 (2004) 4420–4426
Haaften-Day C. van, Shen Y., Xu F. et al., OVX1 macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal, Cancer 92 (2001) 2837–2844
Hellstrom I., Raycraft J., Hayden-Ledbetter M. et al., The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer Res 63 (2003) 3695–3700
Ismail R. S., Baldwin R. L., Fang J. et al., Differential gene expression between normal and tumor-derived ovarian epithelial cells, Cancer Res 60 (2000) 6744–6749
Jones M. B., Krutzsch H., Shu H. et al., Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer, Proteomics 2 (2002) 76–84
Kauff N. D., Satagopan J. M., Robson M. E. et al., Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation, N Engl J Med 346 (2002) 1609–1615
Kim J. H., Skates S. J., Uede T. et al., Osteopontin as a potential diagnostic biomarker for ovarian cancer, Jama 287 (2002) 1671–1679
Kornblith P., Wells A., Gabrin M. J. et al., In vitro responses of ovarian cancers to platinums and taxanes, Anticancer Res 23 (2003) 543–548
Kornblith P., Ochs R. L., Wells A. et al., Differential in vitro effects of chemotherapeutic agents on primary cultures of human ovarian carcinoma, Int J Gynecol Cancer 14 (2004) 607–615
Lancaster J. M., Wooster R., Mangion J. et al., BRCA2 mutations in primary breast and ovarian cancers, Nat Genet 13 (1996) 238–240
Levine D. A., Bonome T., Ohlshen A. B. et al., Gene expression profiling of advanced ovarian cancers to predict the outcome of primary surgical cytoreduction, J Clin Oncol 22, ASCO Annual Meeting Proceedings (2004) Abstract 5000
Li A. J., Madden A. C., Cass I., Leuchter R. S., Lagasse L. D., B. Y. Karlan. The prognostic significance of thrombocytosis in epithelial ovarian carcinoma, Gynecol Oncol 92 (2004) 211–214
Lin Y. W., Lin C. Y., Lai H. C. et al., Plasma proteomic pattern as biomarkers for ovarian cancer, Int J Gynecol Cancer 16, Suppl 1 (2006) 139–146
Massey A., Offman J., Macpherson P., P. Karran, DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells, DNA Repair (Amst) 2 (2003) 73–89
Matei D., Graeber T. G., Baldwin R. L. et al., Gene expression in epithelial ovarian carcinoma, Oncogene 21 (2002) 6289–6298
Miki Y., Swensen J., Shattuck-Eidens D. et al., A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science 266 (1994) 66–71
Mok S. C., Chao J., Skates S. et al., Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology, J Natl Cancer Inst 93 (2001) 1458–1464
Mougeot J. L., Bahrani-Mostafavi Z., Vachris J. C. et al., Gene expression profiling of ovarian tissues for determination of molecular pathways reflective of tumorigenesis, J Mol Biol 358 (2006) 310–329
Ng T. Y., Ngan H. Y., Cheng D. K., L. C. Wong, Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples, Gynecol Oncol 76 (2000) 405–408
Nishizuka S., Chen S. T., Gwadry F. G. et al., Diagnostic markers that distinguish colon and ovarian adenocarcinomas identification by genomic, proteomic and tissue array profiling. Cancer Res 63 (2003) 5243–5250
Obeidat B., Latimer J., Can optimal primary cytoreduction be predicted in advanced-stage epithelial ovarian cancer?, Obstet Gynecol Surv 59 (2004) 709–711
Oh J. H., Gao J., Nandi A., P. Gurnani, L. Knowles, Schorge J., Diagnosis of early relapse in ovarian cancer using serum proteomic profiling, Genome Inform 16 (2005) 195–204
Ohishi Y., Oda Y., Uchiumi T. et al., ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma, Clin Cancer Res 8 (2002) 3767–3775
Olivier R. I., Beurden M. van, Lubsen M. A. et al., Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up, Br J Cancer 90 (2004) 1492–1497
Olopade O. I., G. Artioli, Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations, Breast J 10, Suppl 1 (2004) S5–9
Ozols R. F., Optimum chemotherapy for ovarian cancer, Int J Gynecol Cancer 10 (2000a) 33–37
Ozols R. F., Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol 27 (2000b) 47–49
Perez E. A., Pusztai L., M. Van de Vijver, Improving patient care through molecular diagnostics, Semin Oncol 31 (2004) 14–20
Petricoin E. F., Ardekani A. M., Hitt B. A. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572–577
Pieretti M., Hopenhayn-Rich C., Khattar N. H. et al., Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 20 (2002) 11–23
Psyrri D., Bamias A., Yu Z., Markakis S. et al., Molecular predictors for response to carboplatin and paclitaxel (CP) chemotherapy in patients with ovarian cancer, J Clin Oncol 22, ASCO Annual Meeting Proceedings (2004) Abstract 5066
Rebbeck T. R., Lynch H. T., Neuhausen S. L. et al., Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations, N Engl J Med 346 (2002) 1616–1622
Sakamoto M., Kondo A., Kawasaki K. et al., Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray, Hum Cell 14 (2001) 305–315
Scartozzi M., De Nictolis M., Galizia E. et al., Loss of hMLH1 expression correlates with improved survival in stage III–IV ovarian cancer patients, Eur J Cancer 39 (2003) 1144–1149
Simsek T., Ozbilim G., Gulkesen H., Kaya H., Sargin F., Karaveli S., Drug resistance in epithelial ovarian cancer: P-glycoprotein and glutation S-transferase. Can they play an important role in detecting response to platinum-based chemotherapy as a first-line therapy, Eur J Gynaecol Oncol 22 (2001) 436–438
Spentzos D., Levine D. A., Ramoni M. F. et al., A gene expression signature with independent prognostic significance in epithelial ovarian cancer, J Clin Oncol 22 (2004) 4700–4710
Thompson D., Easton D. F, Cancer incidence in BRCA1 mutation carriers, J Natl Cancer Inst 94 (2002) 1358–1365
Wei S. H., Chen C. M., Strathdee G. et al., Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progressionfree survival in patients and identifies candidate epigenetic markers, Clin Cancer Res 8 (2002) 2246–2252
Wei S. H., Brown R., Huang T. H., Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response?, Ann N Y Acad Sci 983 (2003) 243–250
Welsh J. B., Zarrinkar P. P., Sapinoso L. M. et al., Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer, Proc Natl Acad Sci U S A 98 (2001) 1176–1181
Wong K. K., Cheng R. S., Mok S. C., Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system, Biotechniques 30 (2001) 670–675
Xu F. J., Yu Y. H., Daly L. et al., OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures, J Clin Oncol 11 (1993) 1506–1510
Literatur
Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMACI gene: a tumor suppressor with lip phosphatase activity. J Nat Cancer Inst 91, 1922–32. 1999
Bois A du, Meier W, Luck HJ et al. Chemotherapy versus hormonal treatment in platinum-and paditaxel refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 13(2), 251–57. 2002
Buttitta F, Marchetti A, Gaducci A et al. p53 alterations are predictive of chemoresistance and aggresivness in ovarian carcinomas: a molecular and immun-histochemical study. Br J Cancer 75, 230–35. 1997
Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M, Tsang BK. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvment of phosphoinoside-3 kinase/Akt pathway. Drug resist Updat 5, 131–46, 2002
Devaraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell death proteases. Nature 388, 300–04. 1997
Eltabbakh GH, Awtrey CS. Current treatment for ovarian cancer. Expert Opin Pharmacoth 2, 109–24. 2001
Fortin A, Creagan SP, MacLaurin JG et al. APAFI is a key transcriptional target for p53 in the regulation of neuronal cell death. J Biol Chem 155, 207–16. 2002
Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer. The role of apoptotic regulators. Reproductive Biol and Endocrinology 1, 66, 2003a. Verfügbar unter www.rbej.com/content/pdf/1477-7827-1-66.pdf [12.9.2008]
Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. p53 is a determinat of Xiap/Akt mediated chemoresistance in human ovarian Cancer. Cancer Res 63 (21), 7081–7088. 2003b
Gordon, Alan N. et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal Doxorubicin versus Topotecan. Journal of Clinical Oncology 19(14), 3312–22. 2001
Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M. Cross-talk between Akt, p53 and MDM-2: possible implications for the regulation of apoptosis. Oncogene 21, 1299–303. 2002
Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Letters 420, 25–27. 1997
Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62, 1087–92. 2002
Jesenberger V, Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 3, 112–21. 2002
Koshiyama M, Fuji H, Kinezaki M, Morita Y, Nanno H, Yoshida M. Immun histochemical expression of topoisomerase llalpha (Topo II alpha) and multidrugresistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indicies of ovarian and endometrial carcinomas. Anticancer Res 21(4B), 2925–32. 2001
Li J, Fenq MF, Kim JM et al. Human ovarian cancer and cisplatin resistence: possible role of inhibitor of apoptosis proteins. Endocrinology 142, 370–80. 2001
Mano MS, Awada A, Di Leo A et al. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gyn Oncol 92, 887–95. 2004
Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/akt pathway promotes translocation of mdm-2 from cytoplasma to nucleus. Proc Natl Acad Sci USA 98, 11598–603. 2001
Meier W, Bois A du, Kuhn W, Pfisterer J, Kimmig R, Olbricht S, Richter B. Topotecan vs. Treosulfan in recurrent ovarian cancer (OC) after initial therapy with platinum and paclitaxel. A prospective randomised phase III study. Proc Am Soc Clin Oncol 22, 450. 2003
Nicolantonio F di, Mercer SJ, Knight LA et al. Cancer cell adaption to chemotherapy. BMC Cancer 5, 78. 2005
Ogawara Y, Kishishita S, Obata T et al. Akt enhanced mdm-2-mediated ubiquitination and degradation of p53. J Biol Chem 277, 21843–50. 2002
Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis proteininduces apotosis in chemoresistant human ovarian cancer cells. Cancer Res 60, 5659–66. 2000
Simsek T, Ozbilim G, Gulkesen H, Kaya H, Sargin F, Karaveli S. Drug resistance in epithelial ovarian cancer: P-Glycoprotein and Gluthadion S-transferase. Can they play an important role in detection response to platinum-based chemotherapy as a first-line therapy. Eur J Gynecol Oncol 22(6), 436–38. 2001
Verhagen AM, Coulson EJ, Vaux DL. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genom Biol 2 (Reviews3009). 2001
Yang YL, Li XM. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 10, 169–77. 2000.
Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ Akt2 inhibition in cisplatin-induced JNK/p38 and Bax activation by phosphorylation of Ask I: Implication of Akt2 in chemoresistance. J Biol Chem 278(26), 23432–23440. 2003
Literatur
Alagoz T, Buller RE, Berman M et al. What is a normal CA 125 level? Gynecol Oncol 1994; 53 (1): 93
Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7 (Suppl 5): 20–8
Averette HE, Steren H, Nguyen HN. Screening in gynecologic cancers. Cancer 1993; 72: 1043
Bast RC Jr, Feeney M, Lazarus H et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331–1337
Bast RC Jr, Klug TL, St John E et al. Radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–887
Bast RC Jr, Xu FJ, Yu YH et al. CA 125: the past and the future. Int J Biol Markers 1998; 13 (4): 179–87
Bell R, Petticrew M. Screening people with a family history of cancer. Benefit of screening for ovarian cancer is unproved. BMJ 1997; 15; 315(7118): 1306
Bell R, Petticrew M, Luengo S et al. Screening for ovarian cancer: a systematic review. Health Technol Assess 1998; 2 (2): i–iv, 1–84
Berkowitz RS. CA 125 measurement in epithelial ovarian cancer: A 10-year anniversary of clinical investigation. Gynecol Oncol 1993; 49: 1
Bourne TH, Campbell S, Reynolds K et al. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol Oncol 1994; 52 (3): 379
Bridgewater JA, Nelstrop AE, Rustin GJS et al. Comparison of standard and CA-125 response criteria in patient with epithelial ovarian cancer treated with platinum or paclitaxel. J. Clin Oncol 1999; 17: 501–508
Buller RE, Berman ML, Bloss JD et al. Serum CA 125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol 1992; 47 (1): 87
Creasman WT, DiSaia PJ. Screening in ovarian cancer. Am J Obstet Gynecol 1991; 165: 7
D’Aloia A, Faggiano P, Aurigemma G et al. Serum level of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003; 41 (10): 1805–11
Davelaar EM, Bonfer JMG, Verstraeten RA et al. Ca 125: a valid marker in ovarian carcinoma patients treated with paditaxel? Cancer 1996; 78 (1): 118–27
Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002; 360 (9327): 169–170
Dorum A, Kristensen GB, Abeler VM et al. Early detection of familial ovarian cancer. Eur J Cancer 1996; 32 (10): 1645
Duffy MJ, Bonfrer JM, Kulpa J et al. CA 125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15 (5): 679–91
Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654–2666
Eisenhauer EA, Vermorken JB, Glabbeke M van. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997; 8: 963–968
Elwood M. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002, 360 (9327): 170
Fung MF, Bryson P, Johnston M et al. Screening postmenopausal women for ovarian cancer: a systematic review. J Obstet Gynaecol Can 2004; 26 (8): 717–28
Gaducci A, Ferdeghni M, Prontera C et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevence for differential diagnosis. Gynecol Oncol 1992; 44 (2): 147
Gaducci A, Zola P, Landoni F et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 1995; 58 (1): 42
Gronlund B, Hansen HH, Hogdall C et al. Do CA 125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? Br J Cancer 2004a; 90 (2): 377–82
Gronlund B, Hogdall C, Hilden J et al. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemortherapy of ovarian carcinoma? J Clin Oncol 2004b; 22 (20): 4051–8
Guastalla JP, Vincent P, Le Rol A et al. CA 125 evaluation of chemotherapy response in patients with recurrent ovarian cancer: Rustin criteria revisited. Proc Am Soc Clin Oncol 2002; 21: 204a
Hawkins RE et al. The clinical correlates of serum CA 125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer 1989; 60 (4): 634
Hensley ML, Robson ME, Kauff ND et al. Pre-and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Gynecol Oncol 2003; 89 (3): 440–6
Herberman RB. Uses and limitations of tumor markers. In: Fishman WH (ed) Oncodevelopmental markers, biologic, diagnostic and monitoring aspects. Academic Press, New York 1983
Hogberg T, Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand 1990; 69: 423
Jacobs I, Oram D, Fairbanks J et al. A risk of malignancy index incorporating CA 125, ultrasound and men opausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97 (10): 922
Jacobs I, Davies AP, Bridges J et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993; 306 (6884): 1030
Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353 (9160): 1207–1210
Jeyarajah AR, Ind TE, Skates S et al. Serum CA 125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. Cancer 1999; 85 (9): 2068–2072
Karlan BY, Baldwin RL, Lopez-Luevanos E et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999; 180 (4): 917
Kauff ND, Hurley KE, Hensley ML et al. Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up. Cancer 2005; 104 (2): 314–20
Kreienberg R. Allgemeine und spezifische Laborparameter im Rahmen der Tum ornachsorge bei gynäkologischen Malignomen und bei Mammakarzinomen. Gynäkologe 1989; 22: 55
Lambert HE, Rustin GJ, Gregory WM et al. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 1997; 8: 327–333
Lynch HT. Genetic risk in ovarian cancer. Gynecol Oncol 1992; 46: 1
Makar AP, Kristensen GB, Kaern J et al. Prognostic value of pre-and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992; 79 (6): 1002
Makar AP, Kristensen GB, Bormer OP et al. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? Gynecol Oncol 1993a; 49 (1): 3
Makar AP, Kristensen GB, Bormer OP et al. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol Oncol 1993b; 49 (1): 73
Malkasian GD, Knapp RC, Lavin PT et al. Pre-operative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign and malign disease. Am J Obstet Gynecol 1988; 159: 341
Markman M. A proposal to use CA-125 to evaluate activity of new antineoplastic agents in ovarian cancer. Gynecol Oncol 1993; 51: 297–298
Markman M, Kennedy A, Kim J. Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy. Gynecol Oncol 2001; 83 (3): 593–5
Meeuwissen PA, Seynaeve C, Brekelmans CT et al. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 2005; 97 (2): 476–82
Meier W, Stieber P, Fateh-Moghadam A et al. Prognostische Bedeutung der CA 125 Halbwertszeit für den weiteren Krankheitsverlauf beim Ovarialkarzinom. Geburtsh Frauenheilkd 1992; 52: 526
Meier W, Römisch M, Hepp H. Stellenwert der Rezidivchirurgie beim Ovarialkarzinom. Geburtsh Frauenheilkd 1993; 53: 30
Meier W, Baumgartner L, Stieber P et al. Significance of tumor marker determinations in the primary therapy of ovarian cancer. Anticancer Research 1997a; 17: 2949–2952
Meier W, Baumgartner L, Stieber P et al. CA 125 based diagnosis and therapy in recurrent ovarian cancer. Anticancer Research 1997b; 17: 3019–3020
Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992; 44: 207
Moss EL, Hollingworth J, Reynolds TM. The role of CA 125 in clinical practice. J Clin Pathol 2005; 58 (3): 308–12
Nagele F, Petru E, Medl M et al. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995; 86 (2): 259
Ng LW, Homesley HD, Barrett RJ et al. CA 125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer. Am J Clin Oncol 1989; 12: 106–109
O’Brien TJ, Beard JB, Underwood LJ et al. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001; 22: 348–366
Olivier RI, Lubsen-Brandsma MA, Verhoef S, Beurden M van. CA 125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006: 100 (1): 20–6
Onsrud M. Tumour markers in gynaecologic oncology. Scand J Clin Lab Invest Suppl 1991; 206: 60
Parker D, Bradley C, Bogle SM et al. Serum albumin and CA 125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynaecol 1994; 101 (10): 888
Paulsen T, Marth C, Kaem J et al. Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients. Gynecol Oncol 2000; 76 (3): 326–30
Pearl ML, Yashar CM, Johnstone CM et al. Exponential regression of CA 125 during salvage treatment for ovarian cancer with taxol. Gynecol Oncol 1994; 53: 339–343
Petricoin EF III, Ardekani AA, Hitt BA et al. Uso of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359 (9306): 572–577
Podczaski E, Whitney C, Manetta A et al. Uso of CA 125 to monitor patients with ovarian epithelial carcinomas. Gynecol Oncol 1990; 33: 193
Roman LD, Muderspach LI, Burnett AF et al. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility? J Reprod Med 1998; 43 (5): 403
Rosen A, Sevelda P, Klein M et al. A CA 125 score is a prognostic index in patients with ovarian cancer. Arch Gynecol Obstet 1990; 247 (3): 125
Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21 (10 Suppl): 187–93
Rustin GJ, Nelstrop A, Stilwell J et al. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur J Cancer 1992; 28: 79–82
Rustin GJ, Burg ME van der, Berek JS. Advanced ovarian cancer. Tumor markers. Ann Oncol 1993; 4 (Suppl 4): 71–77
Rustin GJ, Nelstrop AE, Tuxen MK et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996a: 7: 361–364
Rustin GJ, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996b; 14: 1545–1551
Rustin GJ, Nelstrop AE, Bentzen SM et al. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 2000; 18 (8): 1733–9
Rustin GJ, Marples M, Nelstrop AE et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001; 19: 4054–4057
Sjövall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and non-malignant diseases. Gynecol Oncol 2002; 85 (1): 175–178
Skates SJ, Xu FJ, Yu YH et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995; 76 (10 Suppl): 2004
Skates SJ, Chang Y, Xu FJ et al. A new statistical approach to screening for ovarian cancer. Tumor Biol 1996; 17: 45
Skates SJ, Menon U, MacDonald N et al. Calculation of the risk for ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21 (10 Suppl): 206–210
Skates SJ, Horik N, Yu Y et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA72-4 and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004; 22 (20): 4059–66
Smith LH, Morris CR, Yasmeen S et al. Ovarian cancer: can we make the clinical diagnosis earlier? Cancer 2005; 104 (7): 1398–407
Sogaard CH, Lindegaard JC, Havsten H et al. Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer. Gynecol Oncol 2005; 97 (2): 410–2
Stenman UH, Alfthan H, Vartiainen J et al. Markers supplementing CA 125 in ovarian cancer. Ann Med 1995; 27 (1): 115
Stieber P, Fateh-Moghadam A. Tumormaker und ihr sinnvoller Einsatz. Der Bay Int 1990; 10: 70
Talbot R. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer. Surg Gynaecol Obstet 1989; 168: 407–412
Tate S, Hirai Y, Takeshima N, Hasumi K. CA 125 regression during neo-adjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol 2005; 96 (1): 143–9
Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Nall Cancer Inst 2000; 92: 205–216
Tingulstad S, Hagen B, Skjeldestad FE et al. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999; 93 (3): 448–452
Tuxen MK, Soletormos G, Combernowsky P. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer 2001; 84 (10): 1301–7
Van der Burg ME, Lammers FB, Putten WJL van, Stoler G. Ovarian cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncol 1988; 30 (3): 307
Van der Burg ME, Lammers FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990; 1: 301–302
Vergote I, Rustin GJS, Eisenhauer ET et al. New guidenlines to evaluate the response to treatment in solid rumors (ovarian cancer). J Natl Cancer Inst 2000; 92: 1534–1535
Yin BW, Lloyd KO. Molecular cloning of the CA 125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276: 27371–27375
Zurawski VR Jr, Orjaseter H, Andersen A et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988a; 42 (5): 677–680
Zurawski VR, Knapp RC, Einhorn N et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 1988b; 30: 7
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Kreienberg, R. et al. (2009). Diagnostik. In: Management des Ovarialkarzinoms. Onkologie aktuell. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68857-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-540-68857-0_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-41987-7
Online ISBN: 978-3-540-68857-0
eBook Packages: Medicine (German Language)